PRTODAY / NewswireToday Free press release distribution service network

Written by / Agency / Source: Repromedix Corp.

Check Ads Availability|e-mail Article


Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

Repromedix Appoints Dr. Michael J. Burns CEO - Repromedix Appoints Dr. Michael J. Burns Chief Executive Officer National reproductive diagnostic laboratory positions for continued growth
Repromedix Appoints Dr. Michael J. Burns CEO

 

NewswireToday - /newswire/ - Woburn, MA, United States, 2007/07/17 - Repromedix Appoints Dr. Michael J. Burns Chief Executive Officer National reproductive diagnostic laboratory positions for continued growth.

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Repromedix Corp., the leading national diagnostic laboratory for advanced reproductive testing, announced today that Dr. Michael J. Burns has been appointed Chief Executive Officer.

“We are delighted that we were able to attract Dr. Burns to Repromedix,” said Jack Davis, Chairman of the Board. With over 25-years experience growing international pharmaceutical and healthcare companies, Dr. Burns brings extensive senior and general management experience in the critical areas of medical research and development, corporate and business development, product licensing and sales force delivery and marketing.”

Dr. Burns comes to Repromedix after having served more than ten years as the President and Chief Operating Officer of Ferndale Laboratories, a leader in the manufacturing and marketing of pharmaceutical products and medical devices. Having joined Ferndale in 1992, Dr. Burns also served as the President of the company’s Pharmaceutical Division and Vice President of Corporate Development. Prior to Ferndale, Dr. Burns held senior management and leadership positions with Yamanouchi Europe B.V., Smith, Kline & French Pharmaceuticals Ltd., and Napp Laboratories Ltd.

“The increasing number of women seeking to have children later in life has significantly contributed to the development of sophisticated and innovative diagnostic techniques in reproductive medicine,” said Paul Kowalski, President and Vice President of Sales. “Repromedix has grown from a pioneer to national leader in infertility diagnostics. We look forward to leveraging Dr. Burns’ industry experience and expertise as we continue to meet the growing need for valuable medical and genetic information that can contribute to the attainment of parenthood for so many.”

“I couldn’t be more excited to join the incredible team of infertility professionals at Repromedix,” said Dr. Michael J. Burns. “I am especially attracted to Repromedix’ decade-long passion for helping doctors help couples start families. I share deeply the company’s entrepreneurial spirit, its commitment to excellence and its vision for future growth and medical partnership opportunities. I look forward to contributing to the company’s continued growth and success.”

A British native, Dr. Burns holds a postgraduate degree in Pharmacology from the University of Nottingham and an undergraduate degree from the University of Reading in Physiology, Biochemistry and Chemistry.

About Repromedix
Repromedix (repromedix.com) is the leading national diagnostic laboratory for advanced reproductive testing. By taking an interdisciplinary approach to clinical infertility testing that encompasses endocrinology, immunology and genetics, Repromedix offers the most comprehensive suite of advanced diagnostic tests that provide valuable information regarding complex problems of reproductive failure. Since its inception in 1995, the company has assisted more than 45,000 patients by conducting over 100,000 diagnostic tests for recurrent pregnancy loss, premature ovarian failure, male infertility and unexplained infertility.

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Written by / Agency / Source: Repromedix Corp.

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick Newswire Today Visibility Checker

 

Distribution / Indexing: [+]

 
 
# # #
 

 
  Your Banner Ad showing on ALL
Pharma/BioTech/Nutrition articles,
CATCH Visitors via Your Competitors Announcements!


Repromedix Appoints Dr. Michael J. Burns CEO

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name Newswire Today and LINK as the source.
 
  Is this your article?
Activate ALL web links and social stream by Upgrading to Press Release PREMIUM Plan Now!

|
Publisher Contact: Lisa Scimemi - Repromedix.com 
781-404-1752 lscimemi[.]repromedix.com
 
Newswire Today - PRZOOM / PRTODAY disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any Repromedix Corp. securities in any jurisdiction including any other companies listed or named in this release.

Pharma/BioTech/Nutrition via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY



Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!


Read Latest Articles From Repromedix Corp. / Company Profile


Read Pharma/BioTech/Nutrition Most Recent Related Newswires:

U.S. FDA Approves New Indication for Ipsen’s Somatuline® Depot (lanreotide) Injection for the Treatment of Carcinoid Syndrome
Genentech Provides Update on First Lampalizumab Phase III Study for Geographic Atrophy, an Advanced Form of Age-Related Macular Degeneration
mProve Health and Greenphire Partner to Deliver a First-of-its-Kind Patient Engagement Solution
FDA Approves Genentech’s Actemra (Tocilizumab) for the Treatment of CAR T Cell-Induced Cytokine Release Syndrome
Greenphire Named to Inc. 5000 for Fifth Consecutive Year
Five Community Health Centers Honored for Innovative Approaches to Medication Therapy Management
FDA Grants Priority Review for Genentech’s Gazyva in Previously Untreated Follicular Lymphoma
ProSci Incorporates Flow Cytometry Screening to Custom Monoclonal Antibody Service
FDA Grants Priority Review to Genentech's Emicizumab for Hemophilia A with Inhibitors
BD Expands Suite of Blood Culture Offerings with New BD BACTEC™ Standard Aerobic & Standard Anaerobic Plastic Bottles
Twist Bioscience Collaborates with Synbio Technologies to Supply Long DNA to Customers
FDA Grants Priority Review and Breakthrough Therapy Designation for Zelboraf (vemurafenib) in Erdheim-Chester Disease with BRAF V600 Mutation
Ipsen Receives Positive CHMP Opinion for Approval of Xermelo® (telotristat Ethyl)
BD Receives FDA 510(k) Clearance for New Immunological Diagnostic System
Positive Phase III Results for Genentech’s Emicizumab in Hemophilia A Published in The New England Journal of Medicine

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
NewswireToday Celebrates 10 Years in Business


PREMIUM Members


Visit  La Bella Bakery Artisan Bakery Arizona

Visit  RightITnow Ltd





 
  ©2017 Newswire Today — Limelon Advertising, Co.
Home | About | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneurs newswire distribution prtoday.com freenewswiredistribution asianewstoday bizwiretoday USA pr UK today - NOT affiliated with PRNewswire as we declined their partnership offer in 2013
 
PRTODAY & NewswireTODAY are NOT affiliated with USA TODAY (usatoday.com)